Literature DB >> 18663759

A study on confidence intervals for incremental cost-effectiveness ratios.

Hongkun Wang1, Hongwei Zhao.   

Abstract

In health policy and economics studies, the incremental cost-effectiveness ratio (ICER) has long been used to compare the economic consequences relative to the health benefits of therapies. Due to the skewed distributions of the costs and ICERs, much research has been done on how to obtain confidence intervals of ICERs, using either parametric or nonparametric methods, with or without the presence of censoring. In this paper, we will examine and compare the finite sample performance of many approaches via simulation studies. For the special situation when the health effect of the treatment is not statistically significant, we will propose a new bootstrapping approach to improve upon the bootstrap percentile method that is currently available. The most efficient way of constructing confidence intervals will be identified and extended to the censored data case. Finally, a data example from a cardiovascular clinical trial is used to demonstrate the application of these methods. (c) 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Mesh:

Year:  2008        PMID: 18663759     DOI: 10.1002/bimj.200810439

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  11 in total

1.  Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  Biostatistics       Date:  2013-02-19       Impact factor: 5.899

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

3.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

4.  Median-based incremental cost-effectiveness ratios with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

5.  Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.

Authors:  Shuai Chen; Jeffrey S Hoch
Journal:  Stat Med       Date:  2022-06-03       Impact factor: 2.497

6.  Median-Based Incremental Cost-Effectiveness Ratio (ICER).

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Stat Theory Pract       Date:  2012-08-10

7.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

8.  Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project.

Authors:  Matteo Franchi; Claudia Vener; Donatella Garau; Ursula Kirchmayer; Mirko Di Martino; Marilena Romero; Ilenia De Carlo; Salvatore Scondotto; Chiara Stival; Matteo Giovanni Della Porta; Francesco Passamonti; Giovanni Corrao
Journal:  Ther Adv Hematol       Date:  2021-02-23

9.  Meta-analysis of economic evaluation studies: data harmonisation and methodological issues.

Authors:  Bhavani Shankara Bagepally; Usa Chaikledkaew; Nathorn Chaiyakunapruk; John Attia; Ammarin Thakkinstian
Journal:  BMC Health Serv Res       Date:  2022-02-15       Impact factor: 2.655

10.  Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.

Authors:  Lorenza Scotti; Andrea Arfè; Antonella Zambon; Luca Merlino; Giovanni Corrao
Journal:  BMJ Open       Date:  2014-03-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.